Updated Living Systematic Review and Meta-analysis of Controlled Trials of Mesenchymal Stromal Cells to Treat COVID-19: A Framework for Accelerated Synthesis of Trial Evidence for Rapid Approval-FASTER Approval.
Aidan M KirkhamAdrian J M BaileyMadeline MonaghanRisa ShorrManoj M LaluDean A FergussonDavid S AllanPublished in: Stem cells translational medicine (2022)
Our updated living systematic review concludes that MSCs can likely reduce mortality in patients with severe or critical COVID-19. A master protocol based on our Faster Approval framework appears necessary to facilitate the more accelerated accumulation of high-quality evidence that would reduce RoB, improve consistency in product characterization, and standardize outcome reporting.
Keyphrases
- coronavirus disease
- systematic review
- sars cov
- drug administration
- meta analyses
- randomized controlled trial
- mesenchymal stem cells
- bone marrow
- clinical trial
- study protocol
- respiratory syndrome coronavirus
- phase iii
- early onset
- cardiovascular events
- phase ii
- cardiovascular disease
- risk factors
- open label
- coronary artery disease
- sensitive detection